Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A $10bn Target: Stelara Sales Break Barrier Ahead Of Biosimilar Launches

Ustekinumab Brand Grows By More Than A Tenth In Final Year Before Competition

Executive Summary

With competition to Stelara due to kick in midway through 2024, the brand now represents a $10bn+ target for biosimilars, according to the latest figures from J&J.

You may also be interested in...



Biocon Stelara Settlement Places Firm Among Earlier US Rivals

Biocon Biologics has secured a launch date for its planned US biosimilar to Stelara that puts it ahead of some of the competition.

Alvotech Clears A Path For 2024 Ustekinumab In Major Global Markets

Alvotech has ensured there won’t be any legal hurdles to overcome as it plots launches via commercialization partners for its AVT04 proposed biosimilar to Stelara in major global markets.

Generics Bulletin Explains: One Year On, US Humira Biosimilars Continue To Struggle For Share

A year to the day since the launch of the first US rival to Humira, adalimumab biosimilars are still struggling to gain a significant foothold in the market. Generics Bulletin looks at the reasons why.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel